Wall Street expects a year-over-year increase in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended December 2024. While this widely-known consensus ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. The generic ...

China geopolitical tensions, China's Fosun Pharmaceutical is in discussions with three global private equity firms to sell ...

Sri Aurobindo Institute of Pharmacy (SAIP), Indore, successfully hosted a National Conference on "Pharma Innovations: ...

It is worth considering Amneal Pharmaceuticals (AMRX), which belongs to the Zacks Medical - Drugs industry. When looking at the last two reports, this pharmaceutical company has recorded a strong ...